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Abstract: Animal venoms comprise a diversity of peptide toxins that manipulate molecular targets
such as ion channels and receptors, making venom peptides attractive candidates for the development
of therapeutics to benefit human health. However, identifying bioactive venom peptides remains a
significant challenge. In this review we describe our particular venomics strategy for the discovery,
characterization, and optimization of Terebridae venom peptides, teretoxins. Our strategy reflects the
scientific path from mollusks to medicine in an integrative sequential approach with the following
steps: (1) delimitation of venomous Terebridae lineages through taxonomic and phylogenetic analyses;
(2) identification and classification of putative teretoxins through omics methodologies, including
genomics, transcriptomics, and proteomics; (3) chemical and recombinant synthesis of promising
peptide toxins; (4) structural characterization through experimental and computational methods;
(5) determination of teretoxin bioactivity and molecular function through biological assays and
computational modeling; (6) optimization of peptide toxin affinity and selectivity to molecular target;
and (7) development of strategies for effective delivery of venom peptide therapeutics. While our
research focuses on terebrids, the venomics approach outlined here can be applied to the discovery
and characterization of peptide toxins from any venomous taxa.
Keywords: venomics; Terebridae; teretoxins; peptide toxins; animal venom; venom peptides; drug
development; drug discovery; peptide therapeutics; drug delivery
1. Introduction
Medicinal treatments have a storied history tied to natural products discovery and development.
Natural products derived from plants and animals have been the source of traditional medicine
for millennia, and more recently have become major sources of chemical diversity as drug leads,
driving research efforts in pharmaceutical drug discovery and development [1,2]. The ascendancy
of natural products was acknowledged with the awarding of the 2015 Nobel Prize in Physiology or
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Medicine for the discovery of two revolutionary therapies based on natural compounds, Avermectin
and Artemisinin. Avermectin has helped to nearly eradicate parasitic worm diseases such as river
blindness and lymphatic filariasis, while Artemisinin represents the most effective treatment for
malaria known to date [3]. The impact of these natural products on improving global human health
is incalculable.
The journey from natural product discovery to therapy has largely focused on small chemical
compounds such as Avermectin and Artemisinin; however, natural peptides are increasingly being
investigated as drug leads in pharmaceutical research [4]. In particular, peptides found in venomous
organisms are a very promising source for drug discovery. Successful examples of drugs developed
from venom peptides include Captopril®, based on a venom peptide from the Brazilian viper and used
to treat hypertension [5,6]; exenatide (marketed as Byetta®), based on the Gila monster venom and used
as an anti-diabetic agent [7]; and ziconotide (Prialt®), based on a venom peptide from the predatory
cone snail Conus magus and used to treat chronic pain [8,9]. Most venom peptides are disulfide-rich
and vary in length from 12–30 residues in cone snails to 40–80 residues in terebrids, scorpions, and
snakes [10–12]. The relatively small size and the stability provided by disulfide bridges that characterize
natural peptides make them ideal candidates for drug leads. Venom peptides are predominantly being
investigated for the development of drug therapies targeted to ion channels and receptors [12–16].
Due to technological constraints, such as size and ease of collection, venomous organisms like snakes
and scorpions have been traditionally singled out for drug discovery research. However, recent
advances in next-generation sequencing (NGS) techniques and improvements in proteomic methods
have allowed venom research to expand and include neglected venomous invertebrates with great
potential, such as the conoideans (Figure 1) [17–19].
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Figure 1. From mollusks to medicine. Overview of venomics approach for discovery, characterization,
and development of therapeutics from Terebridae venom peptides. This strategy begins with a
phylogenetic delimitation of v nomous ter brid lineages to identify the species that are producing
venom to subdue thei rey (shown in red); in yellow, identification of teretoxins through omics
(genomics, transcriptomics, proteomics); in green, synthesis and structural characterization of
teretoxins; in blue, bioactivity assays and identification of molecular targets; and in pink, peptide
optimization and development of delivery methods for potential terebrid therapeutics.
Toxins 2016, 8, 117 3 of 30
The Conoidea superfamily (cone snails, terebrids, and turrids s.l.) is an extremely diverse group
of predatory marine neogastropods divided into 16 families, with several lineages characterized by
having a venom apparatus used for predation [10,19,20]. The genus Conus, the most extensively
studied among the conoideans, and from which the drug ziconotide (Prialt®) was discovered, includes
species that produce very complex venoms with thousands of unique venom peptides, known as
conotoxins or conopeptides [21–27]. As such, it is not surprising that conotoxins have been considerably
studied for several decades. However, the ~700 described species of cone snails represent far less than
half of the over 15,000 species that are estimated to comprise the Conoidea superfamily [28]. The family
Terebridae, commonly known as auger snails, is an understudied lineage of conoideans that also has
venomous representatives [29–33].
There are circa 400 described species of terebrids that live mostly in shallow sandy bottoms on
tropical waters and have a characteristic elongated shell [33–35]. Terebrid venom peptides, referred
to as teretoxins, are structurally similar to conotoxins, but due to the early divergence of terebrids
and cone snails in the Paleocene [36], teretoxins represent highly divergent compounds with unique
functionalities compared to conotoxins [10,19,37–39].
Despite their great potential, characterizing bioactive compounds in conoidean venom poses
several challenges due mainly to their great species diversity, difficulty of sampling due to size and
habitat, the small amounts of venom produced, and the scarcity of reference databases to identify
novel venom peptides [40]. The most promising avenue to overcome these challenges is to apply
interdisciplinary strategies that integrate molecular biology and biochemical analyses of venom
compounds to optimize the characterization of peptides [41]. This strategy, often referred to as venomics,
combines classic approaches for the study of biodiversity, such as taxonomy and phylogeny, with
modern NGS techniques and proteomic methods, creating a robust evolutionary roadmap for effective
drug discovery while greatly advancing knowledge on venom systematics and evolution [16,19,42–44].
In the present review, we describe our specific venomics approach to investigate Terebridae
diversity and evolution, and to identify and characterize teretoxins and their potential for biomedical
applications, paving the scientific route from mollusks to medicine (Figure 1).
2. Phylogeny-Based Discovery of Teretoxins
Traditionally molluscan species were chosen for venom research based on size, ease of collection,
and quantity of venom produced. The lack of a methodological strategy led to the characterization
of random venoms that sometimes corresponded to a mere single lineage [19]. As molecular
biology, NGS, and proteomics technologies advanced, size and quantity of venom were no longer a
restriction and it was possible to devise strategies that harnessed the evolutionary power of nature,
investigating phylogenies and species relatedness to determine the most promising and diverse
conoidean lineages to identify novel bioactive compounds through venomics analyses [22,45–47].
This venomics-based discovery strategy takes into account different characteristics, such as the presence
of a venom apparatus, and demonstrates the importance of understanding phylogeny to enhance the
identification of venom peptides with potential pharmacological applications [19]. We follow this
phylogeny-informed methodology to select appropriate terebrid study lineages and taxa (Figure 2) [10].
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Figure 2. Terebridae phylogeny. Cladogram reconstructing the evolutionary relationships within the
Terebridae family. Line color indicates presence or absence of venom apparatus. Solid red lines indicate
clades in which all members have venom apparatus, dashed red lines indicate clades in which only
some members have venom apparatus, and black lines indicate clades that lack venom apparatus.
Cladogram based on phylogenetic reconstruction from [48].
2.1. Terebridae Phylogenetics
Natural history and elatedness among species have been tradi i nally defined by
morphology-based phylogenetic reconstructions. This methodology is hampered in the Neogastropoda
due to the high levels of homoplasy and convergence in morphological characteristics [49–51]. Thus, the
advantages of molecular phylogenetics, which allows for the comparison of thousands of homologous
characters across species, are of particular interest among the Terebridae.
The first molecular phylogeny of the Terebridae was constructed based on analyses of a
three-gene matrix (12S, 16S, and COI) to define Terebridae lineages and their evolutionary history [52].
This initial Terebridae phylogeny confirmed the monophyly of the group and defi ed five distinct
lineages: Acus (Cl de B), Terebra (Cl e C), Hastula (Clade D), Myurella (Clad E), nd a p eviously
unidentifie fifth sister clade th t include Pellifronia jungi (Clade A) [52]. Subsequ nt molecular
phylogenetic analysis, including additional taxa from the Eastern and Western Pacific further resolved
the terebrid evolutionary relationships, synonymizing Acus clade B to Oxymeris, recovering a previously
unidentified clade F that includes the Euterebra and Duplicara genera, and subdividing the large Myurella
clade E into five lineages (Clades E1–5) [48] (Figure 2). The molecular phylogeny of terebrids correlates
with anatomical features, specifically the presence or absence of the venom apparatus [53].
It is important to mention that the accuracy of phylogenetic reconstructions is not guaranteed
by any particular number of genes or taxa, even when bootstrap support values are high. In many
cases, increasing gene number leads to higher support for the incorrect phylogenetic reconstruction;
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however, increasing taxon representation improves the accuracy, providing a phylogeny that is more
likely to represent the evolutionary history of the group. Therefore, the accuracy of phylogenetic
estimations as well as the accuracy of inferences about evolutionary processes based on phylogenies
can be significantly improved by extensive and thorough taxon sampling efforts [54,55]. This was
evident in the last Terebridae phylogeny published in 2012, which expanded the taxon sampling
from the Western Pacific region to include species from the Eastern Pacific as well. The expansion
of taxon sampling allowed us to substantially refine the relationships of the Myurella clade lineages
and to recover a previously unidentified clade F (Figure 2) [48,52]. For this reason, we are constantly
working on increasing taxon sampling to improve the phylogenetic reconstruction of the Terebridae
and currently have samples of ~150 species, which represents ~38% of the 400 currently known
terebrid taxa.
Another source of conflict when inferring phylogenies is determining the root of the tree. The root
of a tree represents its deepest split and determines the direction of all subsequent evolutionary events.
An incorrect root can result in erroneous inferences of species relationships and character evolution
and, therefore, determining the root accurately is critical for phylogenetic analysis. One of the most
common methods applied to root phylogenetic trees is the use of an outgroup that represents the most
closely related taxa or sister group. Unfortunately, it is not always certain what the closest relatives to a
particular group are and, even when this is known, sometimes the closest relatives are rather distantly
related [56,57]. Luckily, the Conoidean phylogeny has been thoroughly studied and there is extensive
evidence that cone snails and turrids are the most closely related taxa to Terebridae [20,58]. Therefore,
the Terebridae phylogenetic reconstructions are rooted with representative species of Conidae and
Turridae as closely related outgroups and species from the neogastropod family Harpidae as distant
outgroups [52], providing a robust and accurate root for phylogenetic inference.
2.2. Venom Apparatus Evolution
The venom apparatus as defined in the Conidae consists of a venom bulb, a venom gland,
a radular sac, and a proboscis. However, the Terebridae have been traditionally described as having
three distinct foregut anatomies: (I) salivary glands present, but lack of a radular sac and venom
apparatus; (II) identical to a Conus venom apparatus with a radula delivery system and venom gland
for venom production; and (III) lack of a venom apparatus, but presence of an accessory proboscis
structure [59,60]. These early anatomical descriptions have been revised in recent publications and
expanded to include additional important features of terebrid anatomy, such as marginal radular
teeth [61–63]. Terebrids display the widest diversity of marginal radular teeth types in all conoideans
including duplex, solid recurved, flat, semi-enrolled, and hypodermic. These teeth are absent in the
lineages in which the venom apparatus has been lost [48]. Our recent efforts have also revealed that
the evolution of the Terebridae foregut anatomy is rather complex and certain features have originated
independently across the phylogeny, while others including the proboscis, radula, and venom gland
have been lost in several lineages [48]. The venom gland specifically, was lost eight times throughout
Terebridae evolution in clades F, B, and E1, and in certain members of E2, E3, E4, and E5 [48]. This level
of gain and loss of venom-related characters is similar to what has been observed in other venomous
taxa such as fish, lizards, and snakes [64–66].
The morphological diversity of foregut anatomies in the Terebridae is hypothesized to correlate
with the varying diet and feeding strategies among the different terebrid lineages, and it has been
suggested as one of the main drivers of species diversification in the group. Moreover, terebrids
with the Type II feeding apparatus feed on their prey in a manner that mirrors that of cone snails.
Specifically, Hastula and Terebra species use a hypodermic radular tooth at the end of the proboscis
to envenomate their vermivorous prey [32,34,48,59,67,68]. Venom variability in cone snails has been
extensively studied and the differences in peptide diversity and expression patterns among different
species have been attributed to divergent diets and defensive pressures, which in turn drive species
diversification [69–71]. Consequently, we can expect a similar correlation pattern to that of cone
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snails, with increased species numbers in the Terebridae lineages that have venom apparatus, and,
accordingly, a vast diversity of terebrid venom peptides.
As the venom apparatus is not found in all terebrid lineages, the first step to characterize teretoxins
is to successfully identify the lineages that have a venom gland and are actively expressing venom
peptides to subdue their prey or for defensive purposes. The molecular phylogeny and characterization
of terebrid foregut anatomy completed to date provides a roadmap for efficiently identifying the most
promising terebrid lineages for venomics investigation (Figure 2). Understanding the relationships
between terebrid lineages aids in effectively identifying divergent terebrid groups for the discovery of
novel peptides with diverse molecular activities that can be used to further drug discovery research.
3. Teretoxin Identification and Classification
The traditional approach for peptide toxin discovery employed biochemical techniques such as
venom fractionation by Liquid Chromatography (LC), Edman Degradation to determine primary
amino acid sequences, and Mass Spectrometry (MS) to characterize crude venom extracts. However,
with the decreasing costs and increasing efficiency of NGS techniques and improvements in
high-throughput proteomic methods, the venomics landscape is rapidly changing and currently
even organisms that produce exceptionally small quantities of venom can be characterized [72].
Transcriptomic studies of venom duct and venom gland tissue are rapidly growing for a number of
venomous taxa, providing large amounts of data that allow the analysis of expressed gene products
and the identification of a great number of putative peptide toxins [73–77]. However, these studies
also have disadvantages. For example, venom peptides identified by genomic methods cannot be
validated without proteomic evidence [78–83]. Conveniently, modern technologies allow the use of
sequence databases generated from genomic data or available in public databases such as Conoserver
and Tox-Prot to aid in the identification of peptides from proteomic data [84–87]. Additionally, the
large number of putative venom peptides and proteins identified by NGS and high-throughput
proteomics can be classified into gene superfamilies using phylogenetic methodologies to facilitate
their interpretation and assist with functional predictions [10,25].
3.1. Venom Gland Transcriptomics
Venom gland transcriptome studies have proven very useful to characterize putative venom
compounds in small invertebrates such as the Terebridae. We have taken advantage of these methods
and recently published a comparative analysis of the venom gland transcriptomes of two Terebridae
species, providing important insights into terebrid venom composition and evolution [10]. In this
work we developed an in silico bioinformatics pipeline that can be broadly applied to investigate
transcriptomic data from other venomous organisms (Figure 3). The pipeline begins offline with
collection of species and tissue dissections. Specifically, terebrid specimens are collected from tropical
marine habitats and dissected to extract the venom gland, which is flash frozen in liquid nitrogen or
fixed in RNAlater and stored at ´80 ˝C until ready for use. For our purposes, total RNA is extracted
from venom gland tissue with the Qiagen RNeasy Micro Kit following the manufacturer protocol
and sequenced using Illumina HiSeq 2500 with v. 4 technology using a paired end flow cell and
100 ˆ 2 cycle sequencing.
The quality of the raw Illumina sequence reads is then evaluated with FastQC (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc). FastQC generates a profile of sequencing data,
including graphs of quality per base, GC-content, k-mer content, and sequence length distributions
among others, allowing for a quick assessment of potential sequencing errors [88]. Trimmomatic [89]
is subsequently used to trim poor quality reads and to remove any Illumina adapters present and
the processed reads are assembled de novo using Trinity [90,91]. Using Trimmomatic to remove
low-quality reads can lead to a higher quality assembly, but the assembly itself and all putative venom
peptides identified must be treated with caution due to the lack of a reference terebrid genome and
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spectrometry, the actual existence of predicted teretoxins from our pipeline cannot be determined 
with certainty. 
Figure 3. Bioinformatics pipeline for terebrid transcriptome analyses. Summary of bioinformatics
pipeline f identification of puta ive ter toxins from RNA-Seq data. Colors indicate diff rent stages
of the proc ss. Orange indicates RNA extraction and sequencing, yellow indicates raw read quality
filtering, r d indicates transcriptome asse bly, green indicates ORF and signal seque ce prediction
from tra scripts, d purple indicates transcript an otation.
After transcriptome assembly is completed, TransDecoder is used to predict coding regions within
the transcripts. A sequence is classified as a candidate protein-coding region based on nucleotide
composition, open reading frame (ORF) length, and optionally, a match to a Pfam domain [90].
As venom is mainly composed of secreted proteins and peptides, SignalP is then used to predict
signal peptide sequences in these putative protein-coding regions [92]. Using a custom Perl script, all
transcripts surviving these two initial filters are then searched against an in-house venom database
using the BLASTp tool [93]. This database includes all known venom proteins and peptides available
in public databases such as Conoserver and Tox-Prot along with putative teretoxins identified by
our group [85–87]. All transcripts with hits to a protein in the database with an e-value of 1e–5 or
better and sequence similarity of at least 40% are then searched against the NCBI non-redundant (nr)
database using the BLASTx tool with the same e-value and sequence similarity thresholds. The results
from the two BLAST searches are compared, and those with a better hit to a protein in the venom
database are considered putative teretoxins and further investigated. The high variation present in
venoms makes identification via homology comparison potentially error-prone, with a high number of
false positive predictions. Without verification via experimental techniques such as mass spectrometry,
the actual existence of predicted teretoxins from our pipeline cannot be determined with certainty.
Toxins 2016, 8, 117 8 of 30
The amino acid sequences of putative teretoxins are also processed for mapping, annotation, and,
specifically, the assignment of Gene Ontology (GO) terms in BLAST2GO [94,95]. The assignment of
GO terms provides information about putative gene or protein domain functions, strengthening the
identification of candidate teretoxins. BLAST2GO is also used to identify potential venom peptides
when transcripts that encode a signal sequence show no sequence homology to proteins in the venom
database through BLAST searches. In this case, protein family IDs and specific protein domains are
identified through an automated model-based approach based on InterProScan [96,97]. Following this
approach, a carefully curated and annotated final list of candidate teretoxins is generated, allowing the
classification of transcripts into functional categories for comparative studies across taxa.
3.2. Identification of Teretoxin Superfamilies
Conoidean venom peptides have a characteristic structure, namely, a signal peptide sequence
followed by a propeptide region and a terminal cysteine-rich mature peptide. Conotoxins have
been classified into “gene superfamilies” according to the percentage of sequence identity of their
signal peptide [98]. Venom gene superfamilies are hypothesized to reflect the evolutionary history
of the conotoxin multigenic system. Puillandre et al. [99] recently validated this hypothesis and
provided a phylogenetic framework for the classification of novel conotoxins. With the increasing
number of putative conotoxins currently identified though transcriptome sequencing, the phylogenetic
classification of conotoxins into venom gene superfamilies facilitates their interpretation and aids in
predicting their biological function [24,25].
Similar to conotoxins, teretoxins are expressed as a single gene product with a signal sequence,
propeptide region, and a cysteine-rich mature peptide on the C-terminal. While teretoxin gene
sequences have been previously reported, there have been no teretoxin gene superfamilies described
due mainly to lack of available data [37–39]. To address this gap, we recently proposed the first
classification of Terebridae teretoxin gene superfamilies, providing a phylogenetic framework for the
classification of novel terebrid peptides [10]. Escalating the previous definition used to describe a
conotoxin superfamily, we define a teretoxin superfamily using three criteria: (i) independent lineage
with high support values (bootstrap ě70 and posterior probability ě90); (ii) sequence identity within
the superfamily to be greater than or equal to 60%; and (iii) the pattern of cysteines is different than in
the sister clade. Through comparative analyses of the venom gland transcriptomes of Terebra subulata
and Triplostephanus anilis, 139 novel putative teretoxins were identified, and following a phylogenetic
approach 14 putative terebrid toxin gene superfamilies were described, 13 of which are unique
to the Terebridae and thus distinct from any currently known conotoxin superfamilies (Figure 4).
The significant differences in the venom profiles of cone snails and terebrids support the premise
that the early divergence of the two neogastropod lineages led to distinct venom cocktails [36].
These results illustrate the power of NGS techniques to provide data that can greatly expand venom
evolutionary research.
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Figure 4. Teretoxin gene superfamilies. Phylogenetic reconstruction of teretoxin gene superfamilies
adapted from [10]. Clades representing teretoxin superfamilies are indicated in blue. The cysteine
framework that characterizes each superfamily is denoted in purple and the corresponding
cysteine scaffold in green. Terebrid superfamily TM is the only one with known homology to a
conotoxin superfamily.
3.3. Venom Proteomics and Proteogenomics A alyses
As most NGS bioinformatics pipelines, the one outlined here to analyze terebrid venom gland
RNA-Seq data, is heavily reliant on sequence homology searches, thus hindering the ability to identify
novel peptide toxins and venom proteins [43]. While ther are som computational m thods such as
InterProScan [96,97] that can aid in the identification of putative venom peptides without sequence
homology to known peptide toxins, the presence of the predicted mature peptides in the venom cannot
be confirmed without proteomic evidence [43].
The best method to date for the characterization of vel venom peptides is through MS
proteomic analyses of venom extracts. Notably, the technology and methodology employed to
identify and validate venom peptides via proteomics analyses has vastly changed in recent years.
In traditional bottom-up proteomics, enzymatic digestions of venom samples, liquid chromatography
(LC), and tandem mass spectrometry (MS/MS) analyses were used to identify venom peptides in
a sample. The bottom-up approach can be useful, but due to loss of peptides during purification
it can prov un u cessful a identifying complete sequences, specially when l oking for novel
peptides. I top-down proteomics, individu l intact venom proteins can be characterized and profiled
using a direct analysis that compares statistically meaningful numbers in the sample to determine
relative expression levels of intact peptides [72,79,100]. While the debate over top-down versus
bottom-up proteomics continues, top-down has several attractive features for de novo venom peptide
identification [101]. The top-down approach involves the analysis of intact proteins typically using
electrospray ionization and high-resolution mass analysis and is being increasingly used to analyze
single proteins or simple protein mixtures, including recent proteovenomic analyses of peptidic and
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small-protein venoms [72,79,102]. For example, Quinton et al. [100] were successful in introducing
a rapid top-down sequencing method that used MALDI matrix enhancing in-source decay (ISD)
to identify disulfide-bridged peptides in Conus venoms. This approach has not only improved the
analysis and characterization of animal venoms, but it has also further enabled the identification of
post-translational modifications (PTMs) [43,103].
PTMs are very common in conotoxins and can impact their specificity and activity [104–106].
The presence of PTMs cannot be reliably inferred from sequence data alone and must be confirmed
by MS analysis of the pure native venom extract [47]. For example, proteomic analysis of the venom
gland of Conus textile identified 31 conotoxins and 25 PTMs, while the venom gland transcriptome
analysis of Conus tribblei revealed 136 putative conotoxins, and no PTMs [78,107]. While the number of
putative conotoxins identified through transcriptomic analyses is much greater, without proteomic
evidence none of the 136 Conus tribblei putative conotoxins can be validated, nor any potential PTMs
identified. Consequently, a combined proteomics–genomics approach, or proteogenomics, represents the
most comprehensive and promising method for the discovery of novel toxins and the characterization
of animal venoms in general, and Terebridae venom in particular [41,43,84]. With this approach,
species-specific protein sequence databases generated from genomic and transcriptomic data are
used to identify novel peptides, not present in reference databases, from proteomic data. In addition,
proteomic data provides evidence of gene expression, validating the gene models predicted from
genomic and transcriptomic data. The venom peptides, validated through proteogenomics methods,
can then be synthesized and characterized to investigate their function and molecular targets.
4. Chemical and Recombinant Peptide Synthesis of Teretoxins
Teretoxins are a valuable reservoir of bioactive compounds; however, due to the scant quantities
of venom produced by terebrids, it is difficult to obtain sufficient amounts of venom peptides for
appropriate biochemical characterization. This obstacle can be overcome by producing synthetic
versions of the peptides found in venom extracts. The three most common ways to obtain venom
peptides synthetically are liquid-phase peptide synthesis (LPPS), solid-phase peptide synthesis (SPPS),
and recombinant biology techniques [72,108,109]. Each method has advantages and disadvantages,
such as the inexpensiveness and simplicity of LPPS that comes at the cost of yield and time. SPPS in
turn, offers rapid syntheses, but depending on the peptide, obtaining the native cysteine fold can
be problematic [110]. Recombinant synthesis allows for high yield and purity, but does not easily
permit the incorporation of unnatural amino acids or site-specific labeling of peptides. The typically
small volume of venom produced by terebrids requires multiple synthetic approaches including both
chemical and recombinant synthesis methods [72,111].
4.1. Solid Phase Peptide Synthesis
SPPS was first developed by Robert Bruce Merrifield in the second half of the twentieth century
and has become a standard synthesis method for both peptides and proteins [112]. Through SPPS
venom peptides can be rapidly synthesized, allowing the incorporation of unnatural amino acids and
peptide backbone modification. The SPPS initiates on the carboxylic end of the last amino acid in a
peptide sequence, which is bound to an insoluble solid support or resin. In this technique, a three-step
deprotection, activation, and coupling process is repeated until the peptide of interest is completed,
at which point it is removed by cleavage from the solid support resin (Figure 5A). The insoluble nature
of the resin allows excess reagent to be used to drive the amino acid coupling reaction to completion,
and then all excess is washed away at each step in preparation for the next reaction. In the first SPPS
iteration, the amino-terminus of each amino acid is protected from unwanted reaction by an acid
labile tert-Butyloxycarbonyl (BOC) group. In the past few decades several solid support resins have
been developed, as well as the now widely used base-labile fluorenylmethyloxycarbonyl (FMOC)
amino-terminus protecting group for amino acids [113,114]. The FMOC protecting group is removed
or deprotected with a strong base and the next amino acid is activated and then added to the growing
Toxins 2016, 8, 117 11 of 30
peptide chain (Figure 5A). Activation facilitates the coupling reaction and a peptide bond is formed
between the amino acid residues (Figure 5A).
Venom peptides, which are typically rich in cysteines, pose several challenges for SPPS. However,
most of these challenges can be overcome by using a copolymer solid support that contains both
polystyrene and polyethylene glycol. The polystyrene and polyethylene glycol copolymer has greater
stability in acidic environments, higher swelling, and prevention of racemization, which is a concern
for any peptide sequence with multiple cysteines or histidines [115]. Another strategy to successfully
synthesize disulfide rich peptides is to increase purity and yield by incorporating pseudoproline
dipeptides to reduce β-sheet formation during synthesis [116]. Typically, cysteine residues are
orthogonally protected using an acetamidomethyl group on select cysteines, and trityl groups on the
remaining cysteines to allow for site-specific deprotection [117]. More recently substituting select
cysteines for selenocysteines [113,118] significantly advanced the synthesis and folding of cysteine rich
venom peptides. SPPS has been the method of choice for the synthesis of several conotoxins and also
for incorporation of unnatural amino acids such as D-amino acids [43,64,110–113]. We have recently
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Figure 5. Chemical synthesis of teretoxin Tv1. (a) Automated cycle of solid-phase peptide synthesis
using FMOC chemistry; (b) RP-HPLC chromatogram of Tv1 synthesis (linear) and folding reaction.
The folded conformation is indicated by the pink diamond and the linear conformation by the yellow
diamond. (c) NMR structure of chemically synthesized Tv1. Disulfide bonds are depicted in yellow.
4.2. Recombinant Synthesis
Recombinant expression techniques are a great alternative for the synthesis of peptides that
are problematic for SPPS due to length or complexity, such as many teretoxins, which can have
a length of up to 70 amino acids. Recombinant expression in Escherichia coli is a well-established
and popular method for the production of recombinant proteins in which the gene of interest is
cloned in an expression vector, transformed into the host, and induced, providing a protein product
ready for purification [119]. There have been several examples published in the literature describing
methodologies for recombinant expression of disulfide-rich peptides [108,120–130]. These studies
highlight important aspects that must be considered for recombinant expression of peptides, including
the choice of a fusion tag, purification method, host species and strain, and cleavage technique.
For example, conotoxin MVIIA from Conus magus, was successfully expressed through a recombinant
methodology using a thioredoxin N-terminal fusion tag, a His-tag for purification, and a BL21 (DE3)
E. coli host without any cleavage of the fusion tag [120]. Another conotoxin, PrIIIE from Conus parius,
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was recombinantly expressed in a similar way, but a small ubiquitin-like modifier (SUMO) was used
as an N-terminal fusion tag, Rosetta-gami B (DE3) was used as the E. coli host, and the fusion tag was
cleaved using SUMO protease [127].
We recently described a method for the recombinant expression and characterization of terebrid
teretoxin peptide Tgu6.1, from Terebra guttata [111]. The teretoxin Tgu6.1 is a novel 44-amino acid
teretoxin peptide with a cysteine scaffold similar to the VI/VII framework (C-C-CC-C-C) of the
I, M, and O-superfamilies found in cone snails. The recombinant Tgu6.1 was synthesized using
a ligation independent cloning strategy with an ompT protease-deficient strain of E. coli. Specific
care in plasmid design was taken to combat challenges commonly associated with recombinant
expression, such as the formation of insoluble protein aggregates in E. coli, proteolytic degradation,
and unfavorable conditions in E. coli cytoplasm that can prevent the formation of disulfide bonds.
In the case of Tgu6.1, thioredoxin was introduced in the plasmid for disulfide folding and solubility
issues, His6-tag and Ni-NTA (nickel-nitrilotriacetic acid) affinity chromatography were used as a
purification method, and enterokinase was applied to site-specifically cleavage Tgu6.1 from the fusion
protein. The recombinantly expressed Tgu6.1 peptide exhibited bioactivity, displaying a paralytic
effect when tested in a bioassay using the native prey or terebrids, Nereis virens (Annelida) [111].
As the demand for therapeutic peptide drugs increases it is crucial to have reliable methods
for obtaining significant amounts of disulfide-rich venom peptides. The recombinant expression
technique applied to Tgu6.1 described above is an effective alternative to SPPS of teretoxins and other
disulfide-rich venom peptides.
5. Characterization of Teretoxin Structure
Determining disulfide connectivity in venom peptides is a fundamental step in establishing
structure–function relationships. The disulfide crosslinks in venom peptides provide the structural
scaffolds that are essential for their recognition at specific receptor sites [131,132]. An important aspect
to determine disulfide connectivity is the ability to sequester fragments containing single disulfide
bonds through MS fragmentation [133]. As most venom peptides are highly disulfide-rich, the number
of disulfide bond isomers rapidly increases with the number (n) of disulfide bonded Cys residues:
the general formula being n!/[(n/2)!2n/2]. Traditionally, the determination of disulfide pairing in
proteins/peptides was extremely labor-intensive, applying separation of proteolytic fragments by
electrophoresis in one dimension, followed by performic acid oxidation and paper chromatographic
separation in the other [134]. A theoretically ideal method to determine disulfide frameworks in venom
peptides is X-ray crystallography as the dense sulfur atoms in the cysteine side chains scatter electrons
well and are therefore readily visible in electron density maps. Unfortunately, the inherent flexibility
and small size of most venom peptides make them difficult to crystallize [133,135]. The most commonly
used methods for characterization of disulfide bonds involve selective reduction and alkylation of the
peptide at low pH followed by Edman sequencing of a panel of partially reduced intermediates or
cleavage of the peptide with proteolytic enzymes followed by isolation and MS/MS analysis of the
resulting fragments [136,137].
5.1. Characterization of Teretoxin Disulfide Motif
We have recently determined the disulfide connectivity of teretoxin Tv1 from Terebra variegata
by MS/MS mapping using a partial reduction and dual alkylation protocol applying TCEP-HCl
(Tris(2carboxyethyl)phosphine hydrochloride) as reducing agent and NEM (N-ethylmaleimide) and
IAM (iodoacetamide) as alkylating agents. Dual NEM/IAM alkylation resulted in Tv1 peptide species
that were labeled with two, four, or six NEM and IAM groups. The location of NEM and IAM
modifications in each of the six partially reduced species was determined by matching the MS/MS
b- and y-series ions to theoretical patterns [72].
The solution structure of Tv1 was independently derived using standard homonuclear proton
NMR techniques on unlabeled folded synthetic peptide to confirm the disulfide bond connectivity
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derived from MS/MS (Figure 5C). Proton assignments were obtained from 2D NOESY and TOCSY
spectra, and carbon chemical shifts were assigned with the help of a natural-abundance 13C-HSQC
spectrum. Disulfide connectivities were then determined based on the proximity of cysteine residues
in the 10 lowest-energy structures and were in agreement with the disulfide bond pattern derived by
MS/MS analysis [72]. Teretoxin Tv1 has a unique fold compared to other venom peptides. The Cys7
to Cys16 β-hairpin is clamped together, and the N- and C-terminal loops are clamped through the
Cys4-Cys20 and Cys5-Cys21 double-disulfide bond arrangement in an antiparallel manner that flattens
the peptide into an ellipsoid shape (Figure 5C).
5.2. In Silico Peptide Structure Determination
With the large numbers of putative venom peptides identified recently through NGS approaches,
it is prohibitively time-consuming and expensive to structurally characterize each of these peptides
using NMR, especially considering that some of the identified peptides might be false positives
that represent artifacts of the NGS assembly methods. Bioinformatics algorithms that predict the
three-dimensional structures of peptides can be used to narrow down which of many candidate peptide
toxins are worthy of experimental characterization [138] (Figure 6). Venom peptide sequences that
fold into three-dimensional structures with high confidence are more likely choices for structural and
experimental characterization than those that do not form stable folds or display many conformations
with no clear global minimum. Using this in silico approach, the number of peptides that are
synthesized and characterized could be significantly reduced to a manageable amount.
Figure 6. Predicting 3D structure of venom peptides. Scatter plot representation of Rosetta scores
for each of the 10,000 attempts to fold α-GID conotoxin from its amino acid sequence. Blue circles
represent each folding attempt and the red circle represents a folding simulation that resulted in the
correct structure. Inset: comparison of α-GID NMR structure (green) and Rosetta structure prediction
(red). Rosetta ab initio folding protocol was used to predict structure and scores were calculated as the
Root-Mean-Square Deviation (RMSD) to the NMR structure of α-GID.
The Rosetta algorithm for protein folding has enjoyed considerable success in accurately
predicting the three-dimensional structure of proteins ab initio from their sequence, including the
prediction of a completely new protein fold [138,139]. Rosetta is well suited for the folding of venom
peptides from their primary sequence as the disulfide connectivity of these peptides significantly
reduces the number of conformations that need to be searched. Even with this constraint, there is
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evidence that a very large amount of sampling will be necessary for accurate structure prediction, as
venom peptide conformations are unusual in that they differ from the typical, globular conformations
of most proteins [140]. Compared to simpler sequence based approaches that neglect to consider
information about the three-dimensional structure of venom peptides, Rosetta can be used as a more
robust filter for screening the more than one million estimated conoidean venom peptides identified
using venomics.
6. Teretoxins Bioactivity Assays and Functionalization
Our integrative venomics strategy follows a funneling approach from organismal to molecular
biology, starting with the description of terebrid venomous lineages and the characterization of
teretoxin peptides, and ending with the identification of specific molecular targets and functions
(Figure 1). In the sections below we describe our particular methodology to investigate teretoxin
bioactivity and molecular targets.
6.1. Biological Assays
To determine the biological activity of selected synthesized teretoxins, peptides are initially tested
on a bioassay using their native prey, polychaete worms (Annelida) (Figure 1). Animal assays have
proven very useful to gain initial phenotypic insight in to the function of conoidean peptides [141].
Teretoxin polychaete assays are conducted by injecting the folded terebrid peptide in the ventral
nerve cord of a polychaete. Two additional polychaetes are usually injected with saline solution as a
negative control, and a well-characterized peptide toxin (e.g., agatoxin) as a positive control [39,72,111].
Two recently characterized teretoxins, Tv1 and Tgu6.1, analyzed using this bioassay caused partial
paralysis in Nereis virens polychaetes [72,111]. As Terebridae native prey, polychaete worms are the
first line of attack to determine bioactivity in terebrid venom peptides. More complex animal assays,
such as rat or mouse models, are the next step and routinely used to assay venom activity [142–147].
While functionality and activity in native prey are not directly tied to drug discovery, conducting
native prey assays ensures that the newly identified peptide is synthesized and folded correctly. It is
important to verify that the peptide scaffold being applied for drug development is an accurate
scaffold. Additionally, screening for venom peptide molecular targets and bioassays for potential
biomedical applications is very labor-intensive, so focusing on peptides that show bioactivity in native
prey narrows the pool of candidates to those that have greater potential. Finally, the phenotypic
response in the native prey can help identify the molecular mechanism of the venom peptide, e.g.,
if it shows paralytic effect or hyperactivity this may suggest a possible molecular ion channel target
based on previous peptides screened. More recently, due to the increasing interest in venom peptides
as candidates for drug discovery, microfluidic techniques using cell cultures are also being applied
to assay crude venom extracts and purified peptide toxins [148,149]. One of the main advantages of
microfluidics is that it allows for fast high-throughput screening of venom peptides to rapidly identify
bioactive compounds and their potential molecular targets.
6.2. Characterizing Molecular Function
Venom peptides typically interact with ion channels and modulate their activities, enabling the
investigation of specific ion channels and their function [150,151]. For that purpose, after bioactivity
is confirmed through a phenotypic screen, the next step is to determine the molecular target of the
peptide toxin. Characterizing the molecular activity of venom peptides is important from a basic
scientific perspective, but also critical from a therapeutic point of view, as knowing the mechanism of
action of a molecule is a prerequisite for moving it through clinical trials. Additionally, identifying the
molecular site of action of venom peptides enables an ensemble of structure-based molecular design
methods to optimize the peptides use as effective drugs. However, identifying the receptors on which
a venom peptide is active can be as difficult as finding a needle in a haystack.
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Virtual screening is a well-established computational method for identifying ligands that interact
with target proteins. It has been applied successfully even to challenging problems such as finding
small molecules that are active at a target protein whose structure is not known, such as a G-Protein
Coupled Receptors (GPCRs) [152]. In theory, virtual screening methods could also be used to identify
the molecular targets of a newly discovered venom peptides. However, in practice this could be
challenging due to the laborious nature of constructing individual models of venom peptides with a
variety of different potential molecular targets—such as nicotinic receptors, voltage-gated sodium and
calcium channels, and Transient Receptor Potential (TRP) channels—and those for which there is no
solved NMR or crystal structure of the peptide or molecular receptor.
Molecular modeling environments that integrate bioinformatics, homology modeling, and
docking algorithms can drastically reduce the time needed to create in silico venom peptide models.
In this regard, virtual screening can be used in conjunction with high-throughput bioassay screening
methods to prioritize which molecular targets to screen against. For example, the Bioluminate software
package (Schrodinger; New York, NY, USA) largely automates all the steps in the homology model
process, including special features that allow more sensitive searches for distant structural homologues
of ion channels to use as templates. The entire homology modeling process takes only a few minutes.
The venom peptide can then be docked against the model using the integrated PIPER protein–protein
docking algorithm. The entire process, including simulation time, takes roughly one hour for a given
ion channel or receptor target. While the results of such an in silico screen may not always be entirely
accurate, they can be improved by including mutagenesis constraints from the literature if available.
Such an effort can thus provide a prioritized list of molecular targets for screening (i.e., start with
sodium channels prior to calcium channels), potentially reducing the time and material necessary to
identify the molecular channels targeted by venom peptides.
Our approach to teretoxin molecular target discovery is to apply computational algorithms to
model the docking of the peptide of interest to a wide range of potential receptors. The docking poses
can be refined with long timescale Molecular Dynamics (MD) simulations of the peptide toxin/receptor
pose. If the peptide remains in a well-defined pose over the timescale of hundreds of nanoseconds
or several microseconds, it suggests that the teretoxin effectively binds the target receptor protein.
These receptors are then selected as the more likely candidates and have the highest priority for
further experimental verification. Alternatively, receptors where the peptide never establishes a
well-defined pose are considered less likely to be the true target of the peptide and are discarded for
experimental testing.
7. Optimization of Venom Peptides for Drug Development
The estimate of available venom peptides from the reservoir of conoidean snails alone is upwards
of one million compounds [19]. Giving this enormous grab bag, it is essential to identify methods for
optimizing the selection of venom peptides for drug development. Prialt®, Byetta®, and Captopril® are
all breakthrough drugs derived from animal venom peptides via different routes, decades after their
initial discoveries [6–8]. However, with the promise of venomics, peptides that lead to therapeutics
can be more effectively identified in a strategic manner. It should be noted that venom peptides,
while more stable due to their disulfide-rich content, are still susceptible to hurdles that prevent
their widespread application as therapeutics, namely poor pharmacokinetics and invasive delivery
methods [153,154]. The sections below outline the strategies that we apply to optimize the potential
biomedical applications of teretoxins.
7.1. Computational Design for Increased Affinity and Selectivity of Peptide Toxins
Native venom peptides have remarkable affinity and specificity for drug targets such as ion
channels and GPCRs. Many venom peptides can readily serve as scaffolds for peptidomimetics or
pharmacological research tools; however, with a few exceptions, most venom peptides often require
derivative versions to be useful as therapeutic leads. A common modification applied to venom
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peptides is devising derivatives to increase affinity for a specific molecular receptor [155,156]. Another
modification often required for peptide toxins is cyclization to increase the potential for oral activity
and longevity for in vivo circulation [157–160].
Traditional methods for identifying specific functional mutations in venom peptides include
trial and error alanine walks through each residue of the peptide. Following this approach,
20 potential functional mutations in conotoxin α-GID and 70 mutants of spider peptide GpTx-1
were identified [161,162]. However, there is no guarantee that any of these alanine mutants will
have the desired pharmacological profile [163]. Moreover, alanine scans followed by synthesis and
characterization of each mutant is costly and time-consuming. A modern alternative to alanine scans
involves bioinformatics algorithms in which different mutations to the peptide toxin can be applied
in silico and their effects on affinity and selectivity of binding to specific receptors can be predicted
computationally [164,165]. The in silico method is both inexpensive and rapid compared to alanine
scans, ensuring that the number of venom peptides examined can be significantly increased.
Rosetta is one of the most widely used and successful algorithms for in silico molecular design [139].
In addition to being used for modeling the 3D structure of proteins, as discussed previously, Rosetta
can also be applied to model and design peptide/receptor complexes, including modules for structural
refinement, protein–peptide docking, and protein design [166–168]. Additionally, Rosetta has recently
been extended to incorporate non-canonical amino acids, therefore it can also model and design
post-translational modifications such as, hydroxylation, sulfation, and others commonly found in
venom peptides [105,169]. We are currently using Rosetta to increase conotoxin and teretoxin selectivity
for specific molecular targets (Figure 7). As part of this effort, we are developing an application inside
the Rosetta framework to more accurately predict peptide toxin affinity and specificity by incorporating
the flexibility of the peptide/receptor complex into the scoring calculation. When complete, this tool
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Figure 7. Structure-guided design of venom peptides. (A) Structure of acetylcholine binding
protein (AchBP) in complex with conotoxin α-PnIA. AchBP subunits (green and purple) have a
pentameric arrange ent around a central pore. Conotoxin α-PnI (red) binds at the interface of
consecutive subunits. (B) Atomic int ractions between α-PnIA at the interface of AchBP subunits.
Hydrophobic interactions (green) are highly preval , but positive and negative interactions re also
present. The AchBP binding pocket is extensively exposed to solvent (gray clouds) complicating the
computational modeling.
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7.2. Identification of Key Residues in Venom Peptides
Rosetta on its own will identify potential residues that can be altered to enhance venom peptide
specificity. However, if we provide Rosetta with the information accumulated through millions of year
of evolution inherent to venom peptide genetic sequences, we can significantly boost its efficiency.
Computational algorithms that estimate sequence evolution such as PAML (Phylogenetic Analysis by
Maximum Likelihood) and HyPhy (Hypothesis testing using Phylogenies), can compute the rate of
non-synonymous to synonymous mutations in a given group of sequences, identifying specific sites of
the venom peptides under positive selection [171–173]. As these sites are not evolutionarily conserved,
with diverse amino acids present in different bioactive peptides, they represent excellent targets to
mutate in silico with Rosetta. By combining Rosetta modeling with evolutionary algorithms, we can
optimize the process of identifying random mutation possibilities, focusing only on those that have
passed the test of millions of years of evolutionary change while maintaining venom peptide bioactivity.
In venom research, evolutionary algorithms have been primarily used to answer questions
about venom peptide evolution [174–178]. Venoms are generally under strong positive selection to
counteract the evolving defenses of their prey in a never-ending predator-prey arms race [179–181].
Although traditionally used to investigate evolutionary patterns, evolutionary algorithms can also be
effectively applied to predict which amino acids can be altered to increase the affinity and selectivity
of a venom peptide to its target [182–184]. For example, PAML was successfully used to identify
four positively selected sites in scorpion α-neurotoxins LqhαIT, Lqh2, Amm8rgp-3, Ac1, Ac4, Lqh3.1,
and Bjα2 that target voltage-gated sodium channels [182]. Two of the four sites identified by PAML
as being positively selected had been previously linked to bioactivity in peptides LqhαIT and Lqh2.
Additionally, after mutagenesis analysis of these positions, the peptides displayed enhanced potency
and selectivity for sodium channels [182–184]. Conversely, another study used similar methods to
investigate evolutionary patterns in scorpion α-neurotoxin receptors, namely the sodium channels
of the scorpion’s prey, and discovered that scorpion venom peptides bind to evolutionarily variable
regions of the sodium channels [185]. Specifically, positively selected sites of scorpion α-neurotoxins
bind to sodium channels sites under relaxed purifying selection [185]. These findings highlight how
venom peptides interact with their molecular targets and indicate specific sites of the peptide and
receptor that could potentially be altered to increase selectivity. Therefore, information derived from
evolutionary algorithms such as PAML and HyPhy can be coupled with Rosetta software to effectively
enhance its predictive properties and increase venom peptide and receptor specificity.
8. Venom Peptide Drug Delivery
The potency and specificity of bioactive peptides have propelled these agents to the forefront of
pharmacological research, but delivery of peptides to their molecular target is a major obstacle to their
widespread application. We have recently devised a Trojan Horse strategy consisting of packaging a
bioactive peptide within a modified protein cage to protect it during transport, and releasing it at the
target site, which has proven to be a very promising delivery method [186] (Figure 8).
As mentioned earlier, a major obstacle to the medical application of molluscan venom peptides,
and indeed peptides in general, is their poor pharmacokinetic profile. In addition, peptides generally
exhibit poor membrane solubility and can be rapidly cleared through the liver and kidneys [154].
Finally, the blood–brain barrier (BBB) prevents neuroactive peptides in the bloodstream from reaching
targets in the central nervous system (CNS), resulting in these compounds being administered through
intrathecal injection [187]. General methods for improving the pharmacokinetic profile of bioactive
peptides are necessary if these compounds are to realize their full therapeutic potential.
There are numerous strategies for improving the pharmacokinetic profile of therapeutic peptides.
One approach is to stabilize the structure of the peptide itself through such methods as peptide
stapling, macrocyclization, or grafting of peptide segments onto a small protein scaffold [157–160,188].
However, as these methods involve changes in secondary and tertiary structure, they can disturb the
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function and bioactivity of the peptide. In addition, these methods are not completely general and
must be specifically adapted to each individual peptide.
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Figure 8. Trojan Horse teretoxin delivery strategy. Schematic overview of peptide drug delivery
via virus-like particle (VLP) nanocontainers. The peptide cargo is first encapsulated in the VLP
using recombinant biology. The VLP exterior is modified with the cell-penetrating peptide HIV-Tat
and norbornen to enable transport to target site and disassembly respectively. The odified
t i r is tr s rt t t t r t sit , is ss l is tri r r s II t l st t
ti cargo is released. The modular strategy outlined allows for substitution of alter ate conjugates,
argo proteins, and disas embly mechanisms.
As an alternative to modifying the peptide, our Trojan Horse strategy involves packaging
the peptide of interest within a macromolecular nanoparticle that can deliver it to its molecular
target and protect it from degradation during transport. Several types of macromolecules have
been investigated as potential drug-delivery nanocontainers including liposomes [189], natural and
synthetic polymers [190], inorganic particles [191,192], DNA origami structures [193], and protein
cages such as ferritins and virus-like particles (VLPs) [194,195]. Nanoparticle delivery systems are
essentially modular, because their packaging, delivery, and targeting properties are determined by the
nanoparticle carrier rather than by the therapeutic compound. As a result, a single delivery system
could be used for the delivery of a diverse array of bioactive venom peptides.
8.1. P22 Nanocontainers for Venom Peptide Drug Delivery
Our recently developed peptide drug delivery ethod repurposes the procapsid fro the
Salmonella typhimurium bacteriophage P22 as a nanocontainer for the delivery of ziconotide (Prialt ,
VIIA) across the blood-brain barrier (BBB) [186]. Similar to other viral capsids, the P22 procapsid
is well-defined, monodisperse, easy to manufacture, and amenable to both chemical and genetic
manipulation [196]. By modifying the scaffold protein that templates the self-assembly of the P22
procapsid, an arbitrary gene product can be incorporated within the procapsid shell [197,198]. Among
the proteins that have been successfully packaged within the procapsid are the fluorescent proteins
EGFP, mCherry, and ziconotide [186,197,199].
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VLPs have a number of significant advantages compared with other macromolecules: First, they
are generally uniform in size and composition and possess defined architectures—traits that can allow
for precise control of pharmacological properties. Second, as proteins, they are biodegradable by
endogenous cellular pathways, reducing the ability to accumulate in an organ. Also, as gene products,
VLPs can be produced relatively easily and in high yields using standard molecular biology protocols.
Finally, a plethora of tried-and-tested protein modification techniques are available for manipulating
the interior and exterior of proteinaceous VLPs such as molecular cloning, standard and unnatural
amino acid mutagenesis, protein bioconjugation, and directed evolution [200].
In general, the adaptation of protein cages for drug delivery involves three distinct steps:
(1) encapsulation of the pharmacological agent within the viral capsid; (2) targeting of the capsid
to the desired site in vivo; and (3) induced disassembly of the capsid and release of the cargo under
physiological conditions (i.e., neutral pH, moderate temperature, and aqueous environment) (Figure 8).
Applying our Trojan Horse strategy, we have successfully transported P22 VLPs loaded with the
conotoxin-derived analgesic ziconotide (Prialt®), across in vitro and in vivo BBB models. Briefly, the
cell-penetrating HIV-Tat peptide (YGRKKRRQRRR) was synthesized, fluorescently labeled, and
activated with maleimidopropionic acid (MPA), then conjugated to a P22 nanocontainer preloaded
with ziconotide and engineered to feature a surface exposed cysteine residue. P22-Tat nanocontainers
translocated the BBB, demonstrating the feasibility of this Trojan Horse strategy [186]. At a size
of ~54 nm in diameter, P22 capsid virus-like particles are significantly larger than the proteins and
quantum dots previously translocated and reported in the literature. This was the first demonstration
of delivery of ziconotide across a BBB model using a nanoparticle delivery system, providing an
alternative route to intrathecal injection, which has thus far been the only delivery method. The results
of this proof-of-concept experiment are promising towards the development of a tunable VLP
nanocontainer for the delivery of peptide therapeutics across the BBB [186,199].
8.2. Release of Venom Peptide at Molecular Target Site
The next step in the adaptation of VLPs for drug delivery, namely controllable disassembly,
remains a challenge, mainly due to the fact that the disassembly mechanism must proceed under
physiological aqueous environment, with moderate temperature and neutral pH. Overcoming this
obstacle requires an integrated approach at the intersection of chemistry and biology, with a particular
emphasis on materials science, structural virology, and protein engineering. Recent advances in
bioorthogonal chemistry have led to the identification of numerous reactions that proceed under
physiological conditions. We are currently investigating the Ring Opening Metathesis Polymerization
(ROMP) triggered by a ruthenium catalyst (Grubbs II catalyst) for the controlled disassembly of the
P22 VLP (Figure 8).
ROMP is a polymerization reaction initiated by a transition-metal catalyst and driven by
the release of ring strain in a cyclic olefin such as cyclobutene, cyclopentene, cis-cyclooctene,
or norbornene [201]. The ROMP disassembly strategy aims to disrupt the capsid architecture
through steric strain brought about by the unfolding polymerization reaction [202–204]. While
most ROMP catalysts, including all of the commercially available catalysts, use ruthenium, ROMP
with molybdenum and tungsten catalysts have also been reported [205]. As we have previously
demonstrated, norbornene is readily attached to the surface of the P22 procapsid through traditional
bioconjugation techniques [186,199]. We have recently found that conjugation of P22-GFP procapsids
with NHS-activated 5-norbornene-2-carboxylic acid yields P22-GFP-Norb procapsids with an average
of 4.12 norbornenes per coat protein monomer, or more than 1700 norbornenes per procapsid [199].
While the coat protein monomer contains 19 lysine residues, not all of these are surface exposed. TEM
analysis revealed that conjugation of norbornene to the capsid surface did not significantly affect
size or morphology. However, treatment of P22-GFP-Norb with Grubbs II catalyst, which initiates
ROMP, produced clusters of P22-GFP-Norb with distorted morphologies that appeared to be joined
by robust bridge structures, suggesting that ROMP occurred at both intra- and inter-nanocontainer
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interfaces [199]. Further investigation remains to be done to characterize the triggered disassembly of
P22 VLPs, but these early results suggest that our Trojan Horse strategy is an effective method for the
delivery of peptide therapeutics, including teretoxins.
9. Conclusions
This review describes our learn-from-nature integrative venomics strategy for the discovery and
characterization of terebrid venom peptides (Figure 1). This multidisciplinary strategy from mollusks
to medicine starts with the phylogenetic delimitation of venomous Terebridae lineages and putative
teretoxins, continues with the chemical and recombinant synthesis of promising peptide toxins and
their structural characterization, followed by assays to determine bioactivity and molecular targets,
and concludes with the optimization of venom peptides as drug leads and the development of effective
strategies for delivery of venom peptide therapeutics. While a significant amount of research remains
to be done, it is clear that venoms are nature’s cocktail for drug discovery and an integrated venomics
strategy is a successful route to identifying the most effective ingredients to develop potent and
selective peptide therapeutics.
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